The immune system, even one as damaged as theirs, can be rebuilt.
In a hospital in Italy, two young adults whose immune systems had turned against their own nervous systems underwent a radical procedure — a complete biological reset using donor stem cells — and emerged, fifteen years later, free of a disease that had been stealing their futures. Neuromyelitis optica, a rare and devastating autoimmune condition, had resisted every conventional treatment offered to them, leaving physicians with little choice but to attempt something rarely tried for this illness: destroying the immune system entirely and rebuilding it from another person's cells. The results, documented over more than a decade and a half, suggest that the human body's capacity for renewal may reach further than medicine has yet dared to test — though not without cost.
- Two patients with a progressive, paralysis-causing autoimmune disease had exhausted all standard treatments and faced worsening disability with no approved path to remission.
- Doctors wiped out their immune systems entirely using chemotherapy, then infused donor stem cells in a high-stakes gamble to reprogram the biological machinery attacking their own nervous systems.
- Over 15 to 16 years of follow-up — the longest ever documented for this disease and procedure — both patients remained relapse-free, their disease-defining antibodies vanishing and never returning.
- One patient rebuilt his life fully: returning to work, starting a family, and living without daily medication; the other regained partial function and shed her dependence on immunosuppressive drugs.
- The procedure left real scars — one patient developed a lasting immune deficiency requiring ongoing treatment, the other was diagnosed with bladder cancer years later, underscoring that resetting the immune system is not without serious consequence.
- Researchers are calling for larger studies before this becomes a broader option, framing it as a last resort for the most severe cases — a powerful but still unproven path that raises as many questions as it answers.
Two people in their late twenties arrived at an Italian hospital carrying a diagnosis with no cure. Neuromyelitis optica — a rare autoimmune disease in which the body attacks the support cells of the brain and spinal cord — had already failed to respond to every immunosuppressive drug available to them. Progressive paralysis and blindness loomed. Doctors proposed something drastic.
Using chemotherapy drugs typically reserved for cancer treatment, physicians stripped both patients' immune systems down to nothing, destroying the rogue B cells producing the antibodies that were dismantling their nervous systems. Into that biological void, they infused stem cells from anonymous donors — cells that would rebuild the immune system from scratch, theoretically free of the faulty programming that had made it self-destructive. The procedure, known as allogeneic hematopoietic cell transplantation, had been used for decades against blood cancers, but its application to NMO was rare and its long-term outcomes largely unknown.
Researchers at Milan's IRCCS San Raffaele Scientific Institute followed both patients for 15 and 16 years — the longest documented follow-up of its kind. What they found was remarkable: neither patient relapsed. The antibodies that had defined and driven their disease disappeared entirely and did not return. One patient, a man, recovered substantially — returning to work, fathering two children, and living without ongoing medication. The other, a woman, regained partial use of her arms and achieved a stable quality of life no longer dependent on daily treatment.
Yet the story carries shadows. The male patient developed a chronic immune deficiency requiring permanent antibody supplementation, and experienced episodes of swollen lymph nodes. The female patient was later diagnosed with bladder cancer and underwent surgery. Neither complication was definitively linked to the transplant, but both were serious reminders that rebuilding an immune system from the ground up is not a clean or risk-free undertaking.
The researchers were measured in their conclusions, emphasizing that this approach should remain a last resort — reserved for younger patients whose disease has proven resistant to all other options, and only when the disease itself poses a greater danger than the procedure. What the two cases demonstrate, however, is something medicine rarely gets to claim: that even a profoundly damaged immune system can be rebuilt, and that the antibodies driving a chronic autoimmune disease can be made to disappear — and stay gone. Whether that proof can be safely extended to more patients is the question larger studies will now need to answer.
Two people in their late twenties walked into a hospital in Italy carrying a diagnosis that had no cure. Neuromyelitis optica, or NMO, is a rare autoimmune disease where the body's own immune system attacks the support cells that hold the brain and spinal cord together. Without intervention, it leads to progressive paralysis, blindness, and severe disability. The standard treatments—expensive immunosuppressive drugs—had failed them both. They were running out of options.
What happened next was radical. Doctors gave them chemotherapy drugs called fludarabine and treosulfan, not to kill cancer but to wipe out their immune systems entirely. The goal was to destroy the B cells responsible for producing the rogue antibodies that were eating away at their nervous systems. Then, once their immune defenses had been stripped bare, they received an infusion of healthy stem cells from anonymous donors. These cells would rebuild their immune systems from scratch, theoretically without the faulty programming that had turned their bodies against themselves.
This procedure, called allogeneic hematopoietic cell transplantation, or alloHCT, is not new. Doctors have used it for decades to treat blood cancers and sickle-cell disease. But using it for NMO was uncommon, and the long-term results were largely unknown. What made this case remarkable was the follow-up: researchers from the IRCCS San Raffaele Scientific Institute in Italy tracked both patients for 15 and 16 years after their transplants, the longest documented follow-up of NMO patients treated this way.
The results were striking. Both patients remained free of disease relapses for more than 15 years without needing ongoing immunosuppressive medication. The antibodies that had been attacking their nervous systems—the AQP4-IgG antibodies that define NMO—disappeared entirely and stayed gone. The male patient's neurological function improved substantially. He returned to work, started a family, and fathered two children. The female patient, though her recovery was less dramatic, regained some use of her arms and achieved what the researchers described as a good quality of life, no longer dependent on daily medication.
But the story is not one of uncomplicated triumph. The male patient developed a chronic immune deficiency that requires ongoing antibody supplementation—his newly rebuilt immune system, it turned out, was not quite complete. He also experienced swollen lymph nodes, though they resolved on their own. The female patient developed bladder cancer years after the transplant and required surgery. Neither complication was definitively proven to be caused by the procedure, but both were serious, and both underscore that immune system resets carry real risks.
The researchers were careful in their conclusions. They noted that alloHCT should be reserved for younger patients whose disease has proven resistant to standard therapies and who have no other options. It is not a first-line treatment. It is a last resort, undertaken only when the disease itself poses a greater threat than the risks of the procedure. "To date, no approved therapy allows patients to remain treatment-free while maintaining sustained disease control and complete disappearance of pathogenic antibodies," they wrote. This procedure, at least in these two cases, achieved exactly that.
The findings suggest a path forward for people with aggressive, untreatable autoimmune diseases. But they also raise questions that only larger studies can answer: Who will benefit most? How can the risks be minimized? And as other immune-reset approaches emerge—some using patients' own cells rather than donor cells—how will this option compare? For now, these two patients represent proof that the immune system, even one as damaged as theirs, can be rebuilt. Whether that proof will translate into a broader treatment option remains to be seen.
Citas Notables
To date, no approved therapy allows patients to remain treatment-free while maintaining sustained disease control and complete disappearance of pathogenic antibodies.— Researchers from IRCCS San Raffaele Scientific Institute
In selected cases, immune system replacement may achieve long-term disease control and possibly a cure, although larger studies are needed to confirm safety and identify appropriate candidates.— Researchers from IRCCS San Raffaele Scientific Institute
La Conversación del Hearth Otra perspectiva de la historia
Why is this different from just giving someone immunosuppressive drugs for the rest of their life?
Because those drugs don't cure anything—they just hold the disease at bay while you take them. The moment you stop, the antibodies come back and the damage resumes. These two patients stopped all medication 15 years ago and stayed well. That's not management. That's remission.
But you said the procedure itself caused serious complications. How is that better?
It's not automatically better. It's a trade-off. One patient now needs antibody infusions because his immune system didn't fully rebuild. The other got cancer. But both would likely be severely disabled or dead without it. The question isn't whether it's risk-free—it isn't. It's whether the risk is worth it when the alternative is progressive paralysis.
Why does wiping out the immune system and rebuilding it work? Doesn't the new one just make the same mistake?
That's the mystery at the heart of it. The new immune system comes from a donor, so it has no memory of attacking the patient's own cells. It's like giving someone a completely different immune system—one that never learned to hate them. But we don't fully understand why that reprogramming sticks, or why it works in some people and not others.
These are just two people. Can you really draw conclusions from that?
No, not broad ones. But 15 and 16 years of follow-up is extraordinarily long for a procedure this drastic. Most studies of transplants measure success in months or a few years. The fact that both patients are still well more than a decade later tells you something real happened—not just temporary improvement.
What happens to the next person who tries this?
That's what the researchers are asking. They're saying this should only be tried in younger patients whose disease has already beaten every other treatment. It's not for people who haven't tried standard drugs yet. And they need bigger studies to figure out who will actually benefit and how to reduce the complications.